Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$0.25
>-$0.01(-0.40%)
At close: 4:00 PM EDT
$0.25
>-$0.01(-0.40%)
Day’s Range― - ―
52-Week Range$0.16 - $2.88
Previous CloseN/A
Volume270.87K
Average Volume (3M)1.87M
Market Cap
$6.78M
Enterprise Value-$1.18M
Total Cash (Recent Filing)$9.96M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding39,894,844
10 Day Avg. Volume524,263
30 Day Avg. Volume1,874,561
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.17
Enterprise Value/Revenue-12.43
Enterprise Value/Gross Profit9.93
Enterprise Value/Ebitda0.09
Forecast
1Y Price Target
$4.25Price Target Upside1600.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
Bulls Say, Bears Say
Bulls Say
Modest Current LeverageA relatively small debt burden reduces near-term interest and refinancing pressure, giving AIM more flexibility while it advances its pipeline. This is a durable balance-sheet advantage, although continued losses mean that financial flexibility still depends on maintaining access to capital.
Debt ReductionExtinguishing a substantial promissory note lowers contractual debt obligations and can simplify the capital structure. Removing this liability may improve financial resilience over the next several quarters, even though the transaction also increases the share count and does not solve the company’s cash needs.
Ampligen Manufacturing ReadinessExpanding manufacturing capability for Ampligen supports execution of ongoing and potential future trials, including a possible Phase 3 pancreatic-cancer study. Better clinical-supply readiness can reduce a key operational hurdle and help the company advance its lead candidate through regulatory development.
Bears Say
Minimal Revenue And Deep LossesThe very small revenue base and deeply negative margins show that AIM has not yet established a commercially self-sustaining business. Persistent operating and net losses limit internal investment capacity and leave future progress dependent on successful development, partnerships, or additional financing.
Persistent Cash BurnOngoing negative operating and free cash flow means the company is consuming cash to fund operations rather than generating resources for growth. This raises the importance of external capital over the next several quarters and can constrain the pace of clinical development or other strategic investment.
Equity Dilution For Balance-sheet ManagementUsing common stock to reduce debt transfers part of the financing burden to existing shareholders and increases dilution risk. Repeated equity-based balance-sheet actions may weaken per-share economics and indicate that AIM’s current operations do not generate enough cash to retire obligations internally.
AIM ImmunoTech News
AIM FAQ
What was AIM ImmunoTech’s price range in the past 12 months?
AIM ImmunoTech lowest stock price was $0.16 and its highest was $2.88 in the past 12 months.
What is AIM ImmunoTech’s market cap?
AIM ImmunoTech’s market cap is $6.78M.
When is AIM ImmunoTech’s upcoming earnings report date?
AIM ImmunoTech’s upcoming earnings report date is Aug 17, 2027 which is in 297 days.
How were AIM ImmunoTech’s earnings last quarter?
AIM ImmunoTech released its earnings results on Aug 10, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.26.
Is AIM ImmunoTech overvalued?
According to Wall Street analysts AIM ImmunoTech’s price is currently Undervalued.
Does AIM ImmunoTech pay dividends?
AIM ImmunoTech pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on AIM ImmunoTech dividends here
What is AIM ImmunoTech’s EPS estimate?
AIM ImmunoTech’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AIM ImmunoTech have?
AIM ImmunoTech has 39,894,844 shares outstanding.
What happened to AIM ImmunoTech’s price movement after its last earnings report?
AIM ImmunoTech reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -7.719%.
Which hedge fund is a major shareholder of AIM ImmunoTech?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AIM ImmunoTech
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
AIM Stock 12 Month Forecast
Average Price Target
$4.25
▲(1600.00% Upside)
Technical Analysis
Ownership Overview
0.39% Insiders
0.07% Mutual Funds
0.03% Other Institutional Investors
99.51% Public Companies and
Individual Investors